BackNRX Pharmaceuticals- Warrants (24/05/2026) Overview

NRX Pharmaceuticals- Warrants (24/05/2026) Total Liabilities

Track NRX Pharmaceuticals- Warrants (24/05/2026)'s total liabilities ($26M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$25.72M
21.47% YoYΔ $-7.03M vs prior year quarter

Peer average / median

Loading

NRX Pharmaceuticals- Warrants (24/05/2026) Total Liabilities History

Loading

NRX Pharmaceuticals- Warrants (24/05/2026) vs. peers: Total Liabilities Comparison

Loading

NRX Pharmaceuticals- Warrants (24/05/2026) Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NRX Pharmaceuticals- Warrants (24/05/2026) (NRXPW) FAQ

NRX Pharmaceuticals- Warrants (24/05/2026)'s total liabilities stands at $26M as of March 2026. That compares with $33M in the prior-year period — down 21.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NRX Pharmaceuticals- Warrants (24/05/2026) reported $26M in total liabilities versus $33M a year earlier — a 21.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $33M in the prior-year period — down 21.5% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how NRX Pharmaceuticals- Warrants (24/05/2026)'s total liabilities evolved across reporting periods, while the comparison chart places NRXPW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. NRX Pharmaceuticals- Warrants (24/05/2026)'s reading of $26M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.